Douglas C Palmer
Overview
Explore the profile of Douglas C Palmer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
66
Citations
9666
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Palmer D, Webber B, Patel Y, Johnson M, Kariya C, Lahr W, et al.
Med
. 2022 Aug;
3(10):682-704.e8.
PMID: 36007524
Background: Adoptive transfer of tumor-infiltrating lymphocytes (TIL) fails to consistently elicit tumor rejection. Manipulation of intrinsic factors that inhibit T cell effector function and neoantigen recognition may therefore improve TIL...
2.
Zhang Y, Vu T, Palmer D, Kishton R, Gong L, Huang J, et al.
Nat Med
. 2022 Aug;
28(10):2219.
PMID: 35953723
No abstract available.
3.
Kishton R, Patel S, Decker A, Vodnala S, Cam M, Yamamoto T, et al.
Cell Rep
. 2022 Aug;
40(5):111153.
PMID: 35926468
Adoptive T cell therapies (ACT) have been curative for a limited number of cancer patients. The sensitization of cancer cells to T cell killing may expand the benefit of these...
4.
Zhang Y, Vu T, Palmer D, Kishton R, Gong L, Huang J, et al.
Nat Med
. 2022 May;
28(7):1421-1431.
PMID: 35501486
Despite breakthroughs in cancer immunotherapy, most tumor-reactive T cells cannot persist in solid tumors due to an immunosuppressive environment. We developed Tres (tumor-resilient T cell), a computational model utilizing single-cell...
5.
Xu N, Palmer D, Robeson A, Shou P, Bommiasamy H, Laurie S, et al.
J Exp Med
. 2020 Dec;
218(2).
PMID: 33382402
CAR T therapy targeting solid tumors is restrained by limited infiltration and persistence of those cells in the tumor microenvironment (TME). Here, we developed approaches to enhance the activity of...
6.
Gurusamy D, Henning A, Yamamoto T, Yu Z, Zacharakis N, Krishna S, et al.
Cancer Cell
. 2020 Jun;
37(6):818-833.e9.
PMID: 32516591
T cells are central to all currently effective cancer immunotherapies, but the characteristics defining therapeutically effective anti-tumor T cells have not been comprehensively elucidated. Here, we delineate four phenotypic qualities...
7.
Vodnala S, Eil R, Kishton R, Sukumar M, Yamamoto T, Ha N, et al.
Science
. 2019 Mar;
363(6434).
PMID: 30923193
A paradox of tumor immunology is that tumor-infiltrating lymphocytes are dysfunctional in situ, yet are capable of stem cell-like behavior including self-renewal, expansion, and multipotency, resulting in the eradication of...
8.
Guittard G, Dios-Esponera A, Palmer D, Akpan I, Barr V, Manna A, et al.
Sci Rep
. 2018 Mar;
8(1):5336.
PMID: 29593227
Cish, participates within a multi-molecular E3 ubiquitin ligase complex, which ubiquitinates target proteins. It has an inhibitory effect on T cell activation mediated by PLC-γ1 regulation, and it functions as...
9.
Vizcardo R, Klemen N, Islam S, Gurusamy D, Tamaoki N, Yamada D, et al.
Cell Rep
. 2018 Mar;
22(12):3175-3190.
PMID: 29562175
Induced pluripotent stem cell (iPSC)-derived T cells may provide future therapies for cancer patients, but those generated by current methods, such as the OP9/DLL1 system, have shown abnormalities that pose...
10.
Eil R, Vodnala S, Clever D, Klebanoff C, Sukumar M, Pan J, et al.
Nature
. 2016 Sep;
537(7621):539-543.
PMID: 27626381
Tumours progress despite being infiltrated by tumour-specific effector T cells. Tumours contain areas of cellular necrosis, which are associated with poor survival in a variety of cancers. Here, we show...